

## ePAT to begin validation testing of new dementia App version

### Highlights:

25 May 2016

#### DIRECTORS

Frank Terranova  
*Non- Executive Chairman*

Jeremy Read  
*Managing Director*

Paul Niardone  
*Non-Executive Director*

Adam Davey  
*Non-Executive Director*

Stephen Kelly  
*Company Secretary*

#### SHARE INFORMATION

ASX Code: MNQ  
Issued Capital:  
296,805,545 Fully Paid  
Shares  
72,936,522 Listed Options  
15,619,853 Unlisted Options

#### CONTACT INFORMATION

Registered Office:  
Unit 1, 47 Park Road  
Milton, QLD 4064  
T: +61 7 3511 6570  
F: +61 7 3369 3305  
[www.minquest.com.au](http://www.minquest.com.au)

#### MEDIA ENQUIRIES

Colin Jacoby  
Professional Public  
Relations Pty Ltd  
T: +61 8 9388 0944  
M: + 61 411 828 073

MinQuest Limited  
ACN: 146 035 127

- **New version of the ePAT dementia App is due for delivery in June 2016**
- **Validation testing of the new version will begin in July 2016**
- **Tests to take place at two Mercy Care aged care homes in Perth Metro Area**
- **Implementation studies to be undertaken with industry partners in the second half of 2016**
- **Data from tests to support application for registration as a medical device in Australia, the European Union and the United States**
- **The total number of people with dementia globally is forecast to increase to 75.6 million by 2030**

MinQuest Limited (ASX: MNQ) ("MinQuest" or "the Company") is pleased to advise Australian-based medical research company Electronic Pain Assessment Technology (ePAT) Pty Ltd ("ePAT") will begin the next round of validation studies of its revolutionary pain assessment App on a group of aged-care residents with dementia.

ePAT is currently in the process of developing an updated version of the ePAT App for dementia, which is due for release for testing at the end of June 2016. The updated App will incorporate previous validation study results to refine the ePAT pain scale (refer to ASX announcement dated 19 May 2016 for more detail on the validation test results).

In July 2016, ePAT will begin further validation studies for the new version of the App on residents with moderate-to-severe dementia from two accredited Australian aged care homes in the Perth Metropolitan Area.

The validation tests will take place at Mercy Place Mandurah and Mercy Place Lathlain aged care homes with a total of approximately 60 residents (30 residents from each facility) taking part in the tests.

ePAT will also undertake implementation studies with industry partners, including BUPA, in the second half of 2016.

ePAT chief executive officer Professor Jeff Hughes said results from this round of tests were expected in October and November 2016.

“The data from these studies, will be used to support the application for registration of the ePAT App for dementia as a medical device in Australia, the European Union and the United States,” Prof Hughes said. “Our aim is to have the dementia App registered in Australia by June 2017.”

Commenting on the upcoming validation studies, Mercy Place National Director Residential Aged Care Anita Ghose said:

“One of Mercy Health's core values is innovation and as such it is imperative to explore technology solutions to assist in the assessment of pain in the elderly and for effective evaluation of strategies implemented to relieve pain for our residents.”

The App, which is based on research developed by Curtin University over the past 3½ years, is being developed and rolled out in two phases; one for patients with dementia who have lost the ability to communicate with their carers and the second for young children who have not yet learnt to speak.

On 19 May 2016, MinQuest announced that further validation test results confirmed an excellent correlation between the ePAT App for dementia and a standard assessment commonly used in Australian aged care homes, the Abbey Pain Scale (APS).

### **Timeline – ePAT for dementia**

The indicative timeline for significant milestones for development, regulatory approval and commercialisation of the ePAT dementia App is presented in the table below.

<b>Milestone</b>	<b>Dates</b>
Validation testing in aged care homes	July – November 2016
Implementation studies in aged care homes	August 2016 – February 2017
Development and lodgement of registration application in Australia and the European Union	July 2016 – February 2017
Analysis of Implementation Data	December 2016 – June 2017
Target for approval of registration in Australia and the European Union	June 2017
Development and lodgement of registration application in the United States	March – June 2017
First sale in Australia	July 2017
First sale in European Union	August 2017
Target for approval of registration in the United States	November 2017
First sale in the United States	December 2017

*Please note: The above dates are indicative only and are subject to change.*

An update to investors, including timeline, on the ePAT for kids App will be provided to the market shortly.

## **About ePAT**

On 14 April 2016, MinQuest announced that it has entered in a binding heads of agreement to acquire 100% of the issued capital of ePAT. ePAT is developing revolutionary mobile medical applications that use facial recognition software to facilitate and improve pain assessment in patients that are unable to communicate.

The App is being developed and rolled out in two phases; one for patients with dementia who have lost the ability to communicate with their carers and the second for young children who have not yet learnt to speak. The ePAT Apps are being developed for the global market, initially for health care professionals and professional carers of patients with dementia and subsequently for parents and carers of young children.

## **Forward Looking Statements**

This announcement contains "forward-looking statements". Such forward-looking statements include, without limitation: proposed developments in the Company's business, estimates of future earnings, the sensitivity of earnings to commodity prices and foreign exchange rate movements; estimates of future production and sales; estimates of future cash flows, the sensitivity of cash flows to commodity prices and foreign exchange rate movements; statements regarding future debt repayments; estimates of future capital expenditures; estimates of resources and statements regarding future exploration results; and where the Company expresses or implies an expectation or belief as to future events or results, such expectation or belief is expressed in good faith and believed to have a reasonable basis. However, forward looking statements are subject to risks, uncertainties and other factors, which could cause actual results to differ materially from future results expressed, projected or implied by such forward-looking statements. Such risks include, but are not limited to competition with the Company's business activities, changes in technology, the ability of the Company to obtain and maintain any required regulatory approvals for its current or proposed business activities, commodity price volatility, currency fluctuations, increased production costs and variances in resource or reserve rates from those assumed in the company's plans, as well as political and operational risks in the countries and states in which we operate or sell product to, and governmental regulation and judicial outcomes. For a more detailed discussion of such risks and other factors, see the Company's Annual Reports, as well as the Company's other filings. The Company does not undertake any obligation to release publicly any revisions to any "forward looking statement" to reflect events or circumstances after the date of this release, or to reflect the occurrence of unanticipated events, except as may be required under applicable securities law.